This Article Full Text Full Text (PDF) All Versions of this Article: 106/3/292    most recent 01.CIR.0000025630.05387.45v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fisher, C. Articles by McMurray, J. Search for Related Content PubMed PubMed Citation Articles by Fisher, C. Articles by McMurray, J. Related Collections Cardio-renal physiology/pathophysiology Endothelium/vascular type/nitric oxide Other Vascular biology

(Circulation. 2002;106:292.)
© 2002 American Heart Association, Inc.

Brief Rapid Communications

Is the Pregnancy Hormone Relaxin Also a Vasodilator Peptide Secreted by the Heart?

Carol Fisher, MBChB, MRCP; Margaret MacLean, BSc, PhD; Ian Morecroft, BSc, PhD; Alison Seed, MBChB, MRCP; Fiona Johnston; Christopher Hillier, BSc, PhD; John McMurray, MD, FRCP, FESC

From the Department of Medicine and Therapeutics (C.F., A.S., J.M.) and the Division of Neuroscience and Biomedical Systems (M.M., I.M.), Institute of Biomedical and Life Sciences, University of Glasgow, Scotland, UK; and the Vascular Assessment Group (F.J., C.H.), Caledonian University, Glasgow, Scotland, UK.

Correspondence to Professor J. McMurray, CRI in Heart Failure, Wolfson Building, University of Glasgow, G12 8QQ, Scotland, UK. E-mail j.mcmurray{at}bio.gla.ac.uk

Background— It has been shown recently that the pregnancy and parturition hormone, relaxin, is secreted by the heart. This study examined the effects of relaxin in small human resistance arteries from the systemic and pulmonary circulations.

Methods and Results— Arteries were obtained from gluteal biopsies and resected lung tissue and studied with the use of wire myography. Cumulative concentration relaxation curves were constructed in systemic arteries with substance P, epoprostenol, atrial natriuretic peptide, and relaxin (concentration range 10^-13 -10^-7M). The maximal responses were 88(±5)%, 67(±10)%, 52(±16)% and 66(±16)%, respectively. Endothelium removal virtually abolished the action of relaxin. Relaxin had no vasodilator effect in pulmonary arteries.

Conclusions— Relaxin is a powerful dilator of systemic resistance arteries secreted by the heart that may contribute to cardiovascular regulation.

Key Words: vasodilation • arteries • endothelium • peptides

This article has been cited by other articles:

				J. McMurray, M. Petrie, K. Swedberg, M. Komajda, S. Anker, and R. Gardner CHAPTER 23 Heart Failure ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]

				J. Novak, J P. Rubin, J. Matthews, and K. P Conrad RELAXIN (Rlx) MEDIATED FAST RELAXATION OF ARTERIES THROUGH PI3 KINASE AND NITRIC OXIDE FASEB J, April 1, 2007; 21(6): A1371 - A1371.

				D. O. Debrah, K. P. Conrad, A. Jeyabalan, L. A. Danielson, and S. G. Shroff Relaxin Increases Cardiac Output and Reduces Systemic Arterial Load in Hypertensive Rats Hypertension, October 1, 2005; 46(4): 745 - 750. [Abstract] [Full Text] [PDF]

				M. Kupari, T. S. Mikkola, H. Turto, and J. Lommi Is the pregnancy hormone relaxin an important player in human heart failure? Eur J Heart Fail, March 2, 2005; 7(2): 195 - 198. [Abstract] [Full Text] [PDF]

				K. P. Conrad and J. Novak Emerging role of relaxin in renal and cardiovascular function Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2004; 287(2): R250 - R261. [Abstract] [Full Text] [PDF]

				B. Hocher, R. Ziebig, R. Krause, G. Asmus, H.-H Neumayer, L. Liefeldt, and J.-P. Stasch Relaxin Is an Independent Risk Factor Predicting Death in Male Patients With End-Stage Kidney Disease Circulation, May 18, 2004; 109(19): 2266 - 2268. [Abstract] [Full Text] [PDF]

				O. D. Sherwood Relaxin's Physiological Roles and Other Diverse Actions Endocr. Rev., April 1, 2004; 25(2): 205 - 234. [Abstract] [Full Text] [PDF]

				C Fisher, C Berry, L Blue, J J Morton, and J McMurray N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure Heart, August 1, 2003; 89(8): 879 - 881. [Abstract] [Full Text] [PDF]

				J. D. Silvertown, B. J. Geddes, and A. J. S. Summerlee Adenovirus-Mediated Expression of Human Prorelaxin Promotes the Invasive Potential of Canine Mammary Cancer Cells Endocrinology, August 1, 2003; 144(8): 3683 - 3691. [Abstract] [Full Text] [PDF]

				C Fisher, S Al-Benna, A Kirk, J J Morton, and J J V McMurray Transcardiac and transpulmonary gradients in the putative new cardiovascular hormone relaxin Heart, July 1, 2003; 89(7): 789 - 790. [Full Text] [PDF]

				X.-J. Du, C. S Samuel, X.-M. Gao, L. Zhao, L. J Parry, and G. W Tregear Increased myocardial collagen and ventricular diastolic dysfunction in relaxin deficient mice: a gender-specific phenotype Cardiovasc Res, February 1, 2003; 57(2): 395 - 404. [Abstract] [Full Text] [PDF]

				T. Dschietzig, C. Bartsch, C. Richter, M. Laule, G. Baumann, and K. Stangl Relaxin, a Pregnancy Hormone, Is a Functional Endothelin-1 Antagonist: Attenuation of Endothelin-1-Mediated Vasoconstriction by Stimulation of Endothelin Type-B Receptor Expression via ERK-1/2 and Nuclear Factor-{kappa}B Circ. Res., January 10, 2003; 92(1): 32 - 40. [Abstract] [Full Text] [PDF]